ClinicalTrials.gg
RecruitingNCT07556822Updated Sep 9, 2026

Phase I Study of HRS-3005 in B-cell Malignancies

A Phase 1 interventional study of HRS-3005 in B-cell Malignancy, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
190
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study is being conducted to evaluate the safety and tolerability of HRS-3005. To explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-3005 in patients with B-cell malignancy.

02

Conditions studied

  • B-cell Malignancy
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years;
  2. (ECOG) performance status score of 0-1;
  3. ≥12 weeks;
  4. or cytologically confirmed B-cell ;
  5. ;
  6. Adequate organ function;
  7. Females of must not be pregnant or lactating. Females of childbearing potential and males with partners of childbearing potential must agree to use effective from the time of until 28 days after the last dose of study treatment;
  8. Voluntary participation with signed informed consent, good compliance, and willingness to complete follow-up visits.

Exclusion criteria

Exclusion Criteria:

  1. Known central nervous system (CNS) involvement by ;
  2. History of other malignancy within 2 years prior to first dose of study drug, except for the disease under study;
  3. Prior stem cell transplantation or CAR-T therapy within 12 weeks before first dose of study drug;
  4. Prior allogeneic hematopoietic stem cell transplantation;
  5. Positive surface antigen (HBsAg) with detectable HBV-DNA at screening;
  6. Positive antibody with detectable HCV-RNA at screening;
  7. Positive antigen/antibody test at screening;
  8. Active fungal, bacterial, and/or viral infection requiring systemic therapy;
  9. Major surgery or significant trauma within 28 days prior to first dose of study drug;
  10. Severe disease of major organ systems;
  11. Prior anti-tumor treatment-related adverse events not recovered to ≤Grade 1 or stable status;
  12. Incomplete from prior anti-tumor therapy before first dose of study drug;
  13. Use of strong or moderate inducers, or strong or moderate CYP3A inhibitors within 14 days prior to first dose of study drug;
  14. administration within 28 days prior to first dose of study drug;
  15. Ongoing alcohol or drug abuse;
  16. Intracranial hemorrhage within 6 months prior to first dose of study drug;
  17. Currently receiving vitamin K antagonists or Factor Xa inhibitors;
  18. History of severe bleeding disorder, such as coagulation factor deficiency or von Willebrand factor (vWF) deficiency;
  19. Inability to swallow oral medication, or presence of severe gastrointestinal disease or prior surgery significantly affecting gastrointestinal function;
  20. Pregnant or lactating females;
  21. Concurrent participation in another interventional clinical study, or less than 1 month between signing and last dose of previous clinical study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    Treatment group A: HRS-3005

    Drug: HRS-3005

Interventions

  • DrugHRS-3005

    HRS-3005

06

What researchers measure

Primary outcomes

  1. Safety Endpoints: Incidence of adverse events (AEs),number of participants with abnormal laboratory test results .

    Time frame: approximately 1 year

  2. MTD(Maximum tolerated dose)

    Time frame: 28 days after treatment initiation

  3. RP2D(Recommended Phase II Dose)

    Time frame: approximately 2 year.

Secondary outcomes

  1. Peak Concentration (Cmax)

    Time frame: 12 weeks after treatment initiation

  2. Time to Peak Concentration (Tmax)

    Time frame: 12 weeks after treatment initiation;

  3. Area Under the Curve (AUC0-t, AUC0-inf)

    Time frame: 12 weeks after treatment initiation;

  4. Half-life (t1/2)

    Time frame: 12 weeks after treatment initiation;

  5. Apparent Clearance (CL/F)

    Time frame: 12 weeks after treatment initiation;

  6. Apparent Volume of Distribution (Vz/F)

    Time frame: 12 weeks after treatment initiation

  7. Objective Response Rate (ORR)

    Time frame: approximately 1 year;

  8. Time to Response (TTR)

    Time frame: approximately 1 year;

  9. Duration of Response (DoR)

    Time frame: approximately 1 year;

  10. Progression-Free Survival (PFS)

    Time frame: approximately 1 year;

  11. Overall Survival (OS)

    Time frame: approximately 1 year

07

Study locations

1 of 1 sites recruiting
  • Hematology Hospital of the Chinese Academy of Medical Sciences
    Tianjin, Tianjin Municipality 300020, China
    Recruiting
    • Lugui Qiu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Oct 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 29, 2026
StartActual
Jun 3, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Dec 2028
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07556822
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Jun 3, 2026
Primary completion
Oct 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 9, 2026

Study contacts

Wanyi Zhai
Contact
wanyi.zhai.wz5@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion